关于内脏脂肪组织和心力衰竭之间的双向因果关系的研究:多变量门德尔随机化和调解分析
Junyi Liao1, Zhiqiang Zhao, Jiayi Song
1Kunshan Hospital of Jiangsu University, Suzhou, Jiangsu, China.
Medicine
|February 3, 2026
概括
内脏脂肪增加了心力衰竭的风险,冠状动脉疾病部分调解了这一联系. 这项门德尔随机化研究证实了内脏脂肪组织是心力衰竭的重要危险因素.
科学领域:
- 心血管遗传学 心血管遗传学
- 代谢疾病研究研究
- 流行病学方法 流行病学方法
背景情况:
- 内脏脂肪与心血管疾病有关,但其在心力衰竭 (HF) 中的直接因果作用需要阐明.
- 了解冠状动脉疾病 (CAD) 等中间途径对于有针对性的干预至关重要.
研究的目的:
- 通过使用孟德尔随机化 (MR) 研究内脏脂肪组织 (VAT) 对心力衰竭风险的因果关系.
- 评估冠状动脉疾病 (CAD) 在增值税和高压之间关联中的调解作用.
主要方法:
- 在欧洲人口中进行双样本孟德尔随机化 (MR) 分析.
- 多变量回归模型以调整甘油三,皮下脂肪和LDL胆固醇.
- 两步调解分析以量化CAD的间接影响.
主要成果:
- 脏脂肪组织 (VAT) 的升高显著增加了心力衰竭 (HF) 的风险 (OR 1.65).
- 在调整其他代谢因素 (OR 1.49) 之后,这种关联仍然显著.
- 冠状动脉疾病 (CAD) 部分介导了12%的增值税和HF风险之间的因果关系.
结论:
- 内脏脂肪组织是心力衰竭的直接因果风险因素.
- 冠状动脉疾病在内脏脂肪和心力衰竭之间的关系中起着部分调解作用.
相关概念视频
Heart Failure II: Pathophysiology
929
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
929
Pathophysiology of Heart Failure
3.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.7K
Heart Failure I: Introduction
886
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
886
Heart Failure VI: Adjunct Therapies
340
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
340
Heart Failure Drugs: Diuretics
971
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
971
Heart Failure V: Medical Management
319
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
319


